Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3627679 | 0.91 | ADRB2 (0.58) | ADRB2MEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL3916568 | 0.91 | ADRB2 (0.58) | ADRB2MEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL13072323 | 0.90 | ADRB2 (0.57) | ADRB2MEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL13595535 | 0.88 | ADRB2 (0.52) | ADRB2MEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL3921989 | 0.84 | ADRB2 (0.58) | ADRB2MEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL3625638 | 0.84 | ADRB2 (0.58) | ADRB2MEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL13596196 | 0.84 | NPC1 (0.54) | ADRB2MEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL3914874 | 0.80 | ADRB2 (0.75) | ADRB2MAPK1 | |
| SCHEMBL13840705 | 0.80 | ADRB2 (0.75) | ADRB2MAPK1 | |
| SCHEMBL19798449 | 0.80 | KMT2A (0.72) | MEN1KMT2AALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318396-A1 | CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY | GILEAD SCIENCES, INC. (US) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318396-A1 | CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY | ADRB1, ADRB2, ADRB3 | ADRB2 2/4885MEN1 3670/4885KMT2A 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.